Froehlich isn't shying away from pharmaceutical companies as he's a contrarian investor and he anticipates increased demand for prescription drugs from a larger, older population.
FORBES: Intelligent Investing Panel
3.
Corporate bonds have "the potential for price pressure as corporate profit growth cools and investor demand softens, " Gross writes in his quarterly outlook for the fund's investors.